
SentiSense
Ctrl+K
Quick tip: Press
to search stocks
A
AMGN
Amgen Inc.
$369.53
+1.93 (+0.53%)
Summary
Stories
News
Metrics
Fundamentals
Recent News
Filter:
Showing 18 of 18 articles
Korea Investment CORP Sells 22,072 Shares of Amgen Inc. $AMGN - MarketBeat
Unknown
•
10 hours ago
•
Negative
Friday Wyckoff scan — market went almost fully neutral after the selloff
Unknown
•
1 day ago
•
Neutral
How long after final interview to hear back at Amgen
Unknown
•
2 days ago
•
Neutral
I scanned 213 US stocks for institutional buying patterns today, here's what showed up
Unknown
•
2 days ago
•
Neutral
Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report? - Yahoo! Finance Canada
Unknown
•
3 days ago
•
Positive
QQQ, AMGN, CRWD, MELI: ETF Outflow Alert - Nasdaq
Unknown
•
3 days ago
•
Neutral
BAX Antibody Market Set for Explosive Growth | AbbVie • Amgen • Bristol-Myers Squibb - openPR.com
Unknown
•
3 days ago
•
Positive
Cytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market
GlobeNewswire Inc.
•
3 days ago
•
Positive
Anyone familiar with current Amgen hiring timelines? (Ghosted after HM interview, Workday says "In consideration")
Unknown
•
3 days ago
•
Neutral
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
Benzinga
•
4 days ago
•
Positive
New Additions for 2026
Unknown
•
4 days ago
•
Neutral
Struggling with new position, desperately need advice
Unknown
•
4 days ago
•
Neutral
My Official $SCHD Q1 Payout Estimate drops later today! 💰 Before I reveal it… what do you think $SCHD Q1 dividend growth will come in at? Here’s all the raises and cuts we’re working with right now👇 $SCHD Q1 2026 Dividend Growth Update As of Mar 4, 2026 EX DIVIDEND: 3/25 PA
Unknown
•
4 days ago
•
Neutral
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - Clinical Trials Exploring GLP-1 Role in NAFLD and NASH Unlock Future Opportunities
GlobeNewswire Inc.
•
4 days ago
•
Positive
2026 ASCO GU Update
Unknown
•
5 days ago
•
Neutral
AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer - Seeking Alpha
Seeking Alpha
•
6 days ago
•
Positive
A Couple's Financial Manifesto, Revisited
The Motley Fool
•
6 days ago
•
Neutral
Auto rejected at Amgen despite meeting every qualification
Unknown
•
6 days ago
•
Neutral
Company Profile
Symbol
AMGN
Market Cap
$199.20B
IPO Date
Jun 17, 1983
CEO
--
Employees
31,500
Sector
--
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Country
United States
Exchange
--
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Read MoreSimilar Stocks
GILD
Gilead Sciences, Inc.
$143.93
-0.83%
REGN
Regeneron Pharmaceuticals, Inc.
$759.86
-0.66%
ABBV
AbbVie Inc.
$230.11
-0.96%
LLY
Eli Lilly and Company
$990.33
+0.72%
BIIB
Biogen Inc.
$184.87
-1.71%